Chunze Li
Genentech · 176 works · 2,528 citations · h-index 31
Top works
- Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2S)-4-(2,5-Difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory Cancer
- Kinesin spindle protein (KSP) inhibitors. Part 4: Structure-based design of 5-alkylamino-3,5-diaryl-4,5-dihydropyrazoles as potent, water-soluble inhibitors of the mitotic kinesin KSP
- Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males
- Discovery of a Potent, CNS‐Penetrant Orexin Receptor Antagonist Based on an N,N‐Disubstituted‐1,4‐diazepane Scaffold that Promotes Sleep in Rats
- Fixed Dosing Versus Body Size—Based Dosing of Therapeutic Peptides and Proteins in Adults
- Comparative Effects of Fibrates on Drug Metabolizing Enzymes in Human Hepatocytes
- Studies on the Chemical Reactivity of 2-Phenylpropionic Acid 1-O-Acyl Glucuronide andS-Acyl-CoA Thioester Metabolites
- Proline bis-amides as potent dual orexin receptor antagonists
- Mechanistic Studies on the Bioactivation of Diclofenac: Identification of Diclofenac-S-acyl-glutathione in Vitro in Incubations with Rat and Human Hepatocytes
- Kinesin spindle protein (KSP) inhibitors. Part 8: Design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP
- Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer
- Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?
- A Robust Method for Determining DNA Binding Constants Using Capillary Zone Electrophoresis
- Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216
- Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design
- Kinesin spindle protein (KSP) inhibitors. Part 6: Design and synthesis of 3,5-diaryl-4,5-dihydropyrazole amides as potent inhibitors of the mitotic kinesin KSP
- Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors
- Characterization of Human Corneal Epithelial Cell Model As a Surrogate for Corneal Permeability Assessment: Metabolism and Transport
- Physiologically Based Pharmacokinetic Modeling as a Tool to Predict Drug Interactions for Antibody-Drug Conjugates
- Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology